Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting [Yahoo! Finance]